Basic Information
Zubsolv
Regulatory Information
EMEA/H/C/004407
November 10, 2017
13
April 1, 2025
Company Information
Spain
Edificio Este Planta 6a World Trade Center Moll De Barcelona S/n 08039 Barcelona
ACCORD HEALTHCARE SL
Active Substances Detail
Buprenorphine hydrochlorideNaloxone hydrochloride dihydrate
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Zubsolv. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Zubsolv. For practical information about using Zubsolv, patients should read the package leaflet or contact their doctor or pharmacist.